VEGFA and neoplasm: Consequently, excess Ang1 may dampen the efficacy of anti‐angiogenic anti‐VEGF or anti‐Ang2 therapies (Huang et al,2009; Daly et al,2013); and that concurrent Ang1 inhibition might additionally allow for the regression of existing tumor blood vessels while Ang2 inhibition prevents the sprouting of new tumor blood vessels (Falcón et al,2009; Coxon et al,2010).